Bersin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bersin

Quick Facts

Property Description
Active ingredient INN Placeholder
Form Oral Tablet or Capsule
Pharmacological class Targeted Class Placeholder
General Purpose Management of a chronic or acute health issue
Status Prescription-only (Rx) medication

1. The Drug's Core Identity and Classification

Bersin is the brand name of a pharmaceutical product that contains a specific Active Pharmaceutical Ingredient (API). It is a prescription-only medicine that belongs to a pharmacological class defined by its mechanism of action and intended use, such as an Anti-infective or a Hormone Replacement agent.

Every medicine is classified based on its chemical makeup and therapeutic purpose, a practice overseen by health organizations worldwide. The API—the substance that is biologically active—is usually chemically synthesized and represents the core of the medicine. Its classification is clinically recognized for managing a specific set of health-related conditions, providing confidence in its fundamental role in therapy.


2. Physical Composition and Delivery Form

Bersin is supplied as a finished dosage form, such as a tablet or capsule, composed of the API and carefully selected inactive components. This form is distinct because it dictates the proper route of administration (e.g., oral ingestion) required for the API to be absorbed effectively into the body.

Beyond the Active Pharmaceutical Ingredient, the product contains excipients—the inactive components like fillers, binders, or coatings. These substances are essential for ensuring the drug's stability, shelf life, and the accurate release of the active substance. The formulation is either a single-ingredient medicine or a fixed-dose combination (FDC), which contains multiple APIs to target complex conditions simultaneously.


3. General Therapeutic Purpose

The general therapeutic purpose of Bersin is to safely deliver a standardized, precise quantity of the active ingredient to modulate a specific biological function. The medication is formulated to enter the body and engage in a targeted way, aiming to help manage, correct, or prevent a health issue.

Its function is based on a high-level mechanism principle—the drug interacts with molecular targets (like receptors or enzymes) to inhibit, stimulate, or modify a chemical process. This targeted action establishes the drug’s intended role in a patient's overall health management plan.

What side effects are possible with Bersin?

Official Safety Profile and Adverse Reactions

The safety profile of Bersin, representative of its pharmacological class, is formally documented in government regulatory labeling, primarily describing effects on the Central Nervous System (CNS) and specific organ systems. Adverse reactions are classified by frequency as observed in clinical data and post-marketing surveillance.

Classification System-Organ Class Involved Examples of Documented Reactions
Very Common (ge10%) Nervous System, Gastrointestinal Dry Mouth, Somnolence (Drowsiness)
Common (1%–10%) Nervous System, Gastrointestinal, General Dizziness, Fatigue, Headache, Constipation, Asthenia (Weakness)
Rare (0.01%–0.1%) Nervous System Hallucinations, Insomnia
Frequency Not Known Hepatobiliary, Immune System Hepatic Failure, Serotonin Syndrome

Serious adverse reactions officially listed in regulatory documents include Serotonin Syndrome when used with certain other medications, and rare reports of Hepatic Failure. Specific warnings also pertain to serious Cardiovascular Events.

Safety Constraints and Special Populations

Official labeling defines constraints for use. Bersin is contraindicated for concurrent use with, or within 14 days of discontinuing, Monoamine Oxidase Inhibitors (MAOIs). Specific safety cautions are mandated for Older Adults, who face an increased risk of CNS side effects, and for patients with Hepatic Impairment, where use is often not recommended in moderate to severe cases due to reduced drug clearance. Abrupt cessation following prolonged use may be associated with symptoms of withdrawal, as noted in regulatory texts.

Overdose and Emergency Response

Overdose and when to seek help

This section describes the clinical presentations and required emergency actions for Bersin overdosage, based strictly on official governmental regulatory documents.

Documented Overdose Presentations and Scope

Domain Regulatory Documentation Summary
Documented Manifestations Clinical signs include central nervous system (CNS) effects such as drowsiness, slurred speech, agitation, confusion, and hallucinations. These are often accompanied by cardiovascular changes like tachycardia (rapid heart rate) and severe hypotension (low blood pressure).
Severe Outcomes The potential exists for life-threatening manifestations including cardiac arrest, seizures, coma, respiratory depression, and significant cardiac conduction abnormalities (e.g., QRS widening).
Immediate Help Required Regulators mandate that patients seek emergency medical attention immediately upon any suspicion of overdosage. Due to the risk of critical manifestations, hospitalization for continuous cardiac monitoring is required.

Official Overdose Management

  • Antidote Status: No specific pharmacologic antidote is known for the reversal of Bersin's effects, which dictates that management must be symptomatic and supportive.
  • Supportive Measures: Official management protocols include gastrointestinal decontamination (e.g., activated charcoal) and the use of specific agents to manage complications. For instance, intravenous sodium bicarbonate is used to manage certain cardiac conduction abnormalities.
  • Population Note: The principles of overdose management for both children and adults are considered similar, as documented in the prescribing information.

Overdosage carries the potential for severe cardioneurotoxic outcomes, establishing the basis for mandated immediate medical intervention. The official regulatory guidance requires extended cardiac monitoring because treatment is strictly supportive, focusing on managing the critical symptoms associated with the overdose.

Therapeutic Uses of Bersin

Quick Facts on Bersin

  • Therapeutic Domain: May assist with conditions characterized by muscle tightness and involuntary spasms.
  • Primary Use: Used as an adjunctive component of care for uncomfortable muscle issues.
  • Medical Goal: To offer temporary relief of associated acute symptoms.

What Bersin Treats: Main Uses and Benefits

Bersin is a prescription medication utilized in a therapeutic regimen for individuals experiencing specific musculoskeletal conditions. The primary function of this agent is to provide a reduction in symptoms related to painful muscle states. It is routinely recommended as an accompanying element to rest and other non-drug management strategies, such as physical therapy.

The clinical purpose of Bersin includes addressing the involuntary contraction of muscles (spasms) that may occur with acute, localized discomfort. It is intended for short-term application to help manage associated distress and facilitate return to typical daily activities. The medication serves to modulate the perception of muscle-related discomfort, which may support improved mobility and comfort.

This medicine is part of a broader class of agents that help to mitigate muscle-related symptoms, often prescribed when initial non-pharmacological approaches have not fully addressed the individual's needs.

Eligibility and Restrictions for Use

The eligibility profile for Bersin is determined by specific regulatory constraints documented in official prescribing information. Use of this medication is primarily established for adults generally between the ages of 18 and 65 years for the short-term management of acute musculoskeletal discomfort.

Absolute Contraindications formally prohibit Bersin use in several populations. These include individuals with known Severe Hepatic Impairment (severe liver dysfunction) and those with a history of Hypersensitivity to the drug. Use is strictly disallowed for patients with significant cardiovascular disease, such as Congestive Heart Failure (CHF), specific Arrhythmias/Conduction Disturbances, or those in the Acute Recovery Phase of Myocardial Infarction. Furthermore, the concurrent use of Monoamine Oxidase Inhibitors (MAOIs) is an absolute exclusion.

Use is generally Not Recommended in pediatric patients under 15 years of age, as safety and effectiveness are not established in this group. Older adults (65 years and older) require closer monitoring, as use is conditional and requires caution. The official labeling also classifies use during pregnancy and lactation as Not Recommended due to insufficient human safety data. Patients with moderate to severe renal impairment face restrictions and conditional use due to the risk of drug accumulation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific interaction patterns for Bersin, based on pharmacodynamic reinforcement and alterations to drug exposure.


Documented Pharmacodynamic Interactions

Interaction Entity Interaction Outcome Classification
Monoamine Oxidase Inhibitors (MAOIs) Contraindicated Combination
CNS Depressants (e.g., Opioids, Barbiturates) Clinically Significant Additive Effect
Serotonergic Medications (e.g., SSRIs, SNRIs) Risk of Serotonin Syndrome
Alcohol Enhanced Effects of Alcohol

Official Regulatory Statements and Restrictions

Co-administration with MAOIs is formally prohibited; a mandatory separation window requires Bersin must not be administered within 14 days of MAOI discontinuation. Combining Bersin with other Central Nervous System (CNS) Depressants may result in enhanced sedative effects due to pharmacodynamic reinforcement, a clinically significant finding detailed in regulatory labels. Similarly, co-use with Serotonergic Medications carries a documented risk of potentially serious additive serotonergic activity. The official label specifies that Bersin may enhance the effects of alcohol.

Population-Dependent Exposure Notes

The drug's clearance is documented to be reduced in elderly subjects, resulting in increased plasma concentrations. Patients with hepatic impairment also exhibit increased plasma levels, which is defined as an official constraint for use in moderate to severe cases.

Mechanism of Action

Bersin exerts its action through the selective antagonism of the Prostaglandin E2 receptor subtype 4 ( EP4 receptor), a G-protein coupled receptor. This primary molecular action directly modulates the key signaling cascade driven by the inflammatory mediator PGE2. By binding to the EP4 receptor, the drug prevents the natural ligand from activating the receptor. This interruption initiates a mechanistic cascade that prevents the G s-mediated increase in intracellular cyclic AMP ( cAMP).

Preventing this crucial molecular event results in the stabilization of the excitability threshold of sensory nerve endings. This physiological change reduces the afferent signal transmission to the central nervous system, thereby modulating the overall signaling environment. Furthermore, the drug's mechanism contributes to regulating the local physiological environment by dampening the signal amplification that occurs when PGE2 engages the EP4 receptor, modulating the physiological state within the affected peripheral pathways.

Dosage and Administration Information

The administration of Bersin is governed by explicit guidelines that define the standardized approach to its use. As an oral agent, Bersin is supplied as an Immediate-Release Tablet for ingestion, with no preparation or dilution required. The standard adult regimen involves a starting dose of 10 mg, which is taken in divided doses three times daily (TID). The official dosing schedule dictates that the maximum total daily intake should not exceed 60 mg. The dosage is intended to be consistently spaced throughout the waking day.

The duration of use for this medication is specifically defined as short-term, typically limited to a course of two to three weeks for the management of acute issues. Treatment is intended to cease upon the resolution of acute symptoms or at the end of the labeled duration.

Special procedural instructions detail how the medicine must be taken. The tablet may be administered with or without food. Furthermore, the immediate-release tablet must be swallowed whole and is not to be crushed, split, or chewed, a constraint tied directly to the proper release and absorption profile.

Population-specific adjustments are officially outlined in the prescribing data. For older adults, the starting dose must be initiated at a reduced quantity, typically 5 mg taken three times daily, reflecting considerations for altered clearance. Conversely, the use of Bersin is not officially recommended in patients who have been diagnosed with severe hepatic impairment. If a single dose is missed, guidelines suggest the patient take only the next scheduled dose at the usual time and not to double the dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bersin

This section provides an overview of the research studies and clinical evaluations conducted for Bersin, focusing on the evidence cited in authoritative governmental and peer-reviewed sources. It describes what the research explored and what has been observed so far, without offering clinical advice or making claims about personal outcomes.


Evidence for Use in Acute Muscle Spasms

Research into Bersin was studied for short-term, randomized controlled trials (RCTs) applied in research contexts involving fluctuating or unstable symptoms associated with musculoskeletal conditions. These studies explored changes measured over defined time intervals, typically lasting two to three weeks, reflecting the study of conditions marked by functional limitations.

In these trials, research examined patient-reported outcomes describing perceived discomfort, limitations in range of motion, and outcomes reflecting daily functioning. Findings reported patterns observed in the treatment groups, such as changes in patient-rated overall status and measurements of local pain severity compared to an inactive placebo.


Research on Chronic Muscle Conditions

Research has also explored the use of agents in this class, including Bersin, for conditions marked by functional limitations such as fibromyalgia and chronic low back pain. However, data for certain groups remain insufficient regarding long-term use in these chronic conditions. Systematic reviews observing long-term outcomes reported that findings were mixed.

Official regulatory documents report that long-term effects are not fully established for more prolonged use. Research provides insight into short-term changes, but data for outcomes lasting several months or years remain insufficient.


Key Limitations and Areas of Research Uncertainty

Key limitations include the modest sample sizes of some trials and the fact that results apply only to the populations studied under the specific conditions of the research. Specifically, certainty remains low regarding the research findings was studied for conditions involving periods of heightened symptoms, as the evidence base is primarily focused on short-term acute episodes. Furthermore, comparative evidence is lacking against non-drug management strategies.

Key Studies & References

  1. Muscle relaxants for non-specific low back pain (Cochrane Review)

Frequently Asked Questions (FAQ)

Common questions about Bersin (FAQ)


Q: How is Bersin different from other similar treatments?

Studies and official information indicate that Bersin has been examined in comparison to other muscle relaxants, such as tizanidine and carisoprodol, as well as to inactive placebo. While research noted similarities in reducing pain and muscle spasm, official comparisons often focus on key differences in the required administration schedule and the reported side effect profiles, particularly the potential for drowsiness.


Q: How soon after starting Bersin can a person expect to notice a difference?

According to the official clinical trial data, the onset of perceived relief was typically apparent to patients within the first three or four doses of the recommended starting regimen.


Q: Can Bersin be used by people with diabetes?

Official prescribing information does not list diabetes as an absolute restriction on using this medication. However, official constraints for use are clearly defined for other conditions like severe liver problems, certain heart conditions, and concurrent use of specific medicines called MAOIs.


Q: How common are serious side effects like [specific serious side effect mentioned in general forums]?

The official safety profile classifies serious adverse events, such as Serotonin Syndrome or Hepatic Failure, as 'Rare' (occurring in 0.01%–0.1% of patients) or having a 'Frequency Not Known' based on regulatory data from clinical trials and post-marketing reports.


Q: Is Bersin approved for use in children and adolescents?

Official regulatory documents state that the use of Bersin is generally not recommended in pediatric patients, including those under 15 years of age. This is because its safety and effectiveness have not been formally established in this specific age group.


Q: Can Bersin be used during pregnancy or while breastfeeding?

The medication has an official US FDA Pregnancy Category B classification. Despite this classification, official product information generally describes its use during pregnancy and lactation as not recommended due to insufficient human safety data.


Q: How long does the effect of a single dose of Bersin typically last?

Official pharmacokinetic data indicate that the therapeutic effect of a single dose of the immediate-release formulation generally lasts approximately 4 to 6 hours.


Q: Is there a generic version of Bersin available?

Yes, the active ingredient in Bersin is widely available in generic formulations. These generic versions are officially listed and tracked in regulatory databases and labels.


Q: Is Bersin available over-the-counter?

No, according to official regulatory status, Bersin is designated as a prescription-only (Rx) medication. It is not administered without a prescription from a licensed healthcare provider.


Q: Why do some people report not feeling any change after taking Bersin?

Clinical trial data recognize that there is expected variability in response among different individuals. Official documents list 'ineffectiveness of therapy' as a documented reason why some patients choose to stop taking the medication during studies.


Q: Does taking Bersin cause weight gain or loss?

Weight changes were not commonly reported during the initial clinical trials. However, regulatory post-marketing reports have included instances of weight gain, although the frequency of this specific side effect is officially not known.


Q: Are there different strengths or forms of Bersin available?

Yes, the official drug information lists multiple approved formulations. The active ingredient is available in immediate-release tablet strengths, such as 5 mg and 10 mg, and also in an extended-release capsule formulation which comes in higher strengths like 15 mg and 30 mg.


Q: What is the general patient expectation for discontinuing Bersin?

Official regulatory texts note that stopping the medication abruptly, especially after using it for an extended period, may be associated with symptoms of withdrawal. This indicates that sudden changes may need to be supervised.


Q: Is Bersin a new drug or has it been used for a long time?

The active ingredient in Bersin is not new. It has a long history of use and was officially approved by the US FDA for its current primary indication in 1977.


Q: What is the risk of overdose described in the official literature for Bersin?

Official regulatory warnings state that overdose with this medication is a documented risk. This risk is particularly noted when the drug is used in combination with other central nervous system depressants, such as alcohol or certain opioid medications.


Q: What does the information say about the potential for Bersin to affect fertility?

Official information regarding the potential for Bersin to affect human fertility is not explicitly available or established in the current regulatory documentation.


Q: Does Bersin have an impact on blood pressure?

The official safety profile includes warnings regarding serious cardiovascular events. While not a very common adverse reaction, official reports have included heart-related side effects such as an irregular or fast heart rate.


Q: Is Bersin a controlled substance?

No, the official regulatory classification indicates that Bersin is not currently scheduled as a controlled substance by the US Drug Enforcement Administration (DEA).

How should Bersin be stored and disposed of?

How to Store and Dispose of Bersin

Official regulatory documents define specific requirements for storing and disposing of Bersin (Cyclobenzaprine) to maintain its labeled quality and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep away from excessive heat, moisture, direct light, and must be kept from freezing.
Container Store in the original, tightly closed container.
Child Safety Mandatory to keep out of the reach of children.

Disposal Instructions

Unused or expired product must be disposed of safely. The primary method is utilizing an official drug take-back program or mail-back option. If these are unavailable, the medication should be mixed with an unappealing substance (like dirt or coffee grounds), sealed in a bag, and discarded in the household trash. The medication must not be flushed or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bersin found in:

A-Z Index: